# The effect of pharmacological agents on uterine junctional zone contractions during mock embryo transfer: a randomised doubleblind study

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
30/09/2004	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/09/2004	Completed	Results
Last Edited	Condition category	Individual participant data
31/03/2020	Pregnancy and Childbirth	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Frank Biervliet

#### Contact details

Academic Department of Obstetrics & Gynaecology Hull & East Yorkshire (NHS) Trust The Princess Royal Hospital Salthouse Road Hull United Kingdom HU8 9HE +44 (0)1482 701151 abc@email.com

# Additional identifiers

EudraCT/CTIS number

**IRAS** number

## ClinicalTrials.gov number

# Secondary identifying numbers

N0084096582

# Study information

#### Scientific Title

The effect of pharmacological agents on uterine junctional zone contractions during mock embryo transfer: a randomised double-blind study

## **Study objectives**

To assess if junctional zone contractions can be reduced by pharmacological agents.

# Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

# Study design

Randomised double-blind study

#### Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

#### Participant information sheet

# Health condition(s) or problem(s) studied

Pregnancy and Childbirth: Embryo transfer

#### **Interventions**

The patient's baseline junctional zone contractions will be established following a 5 minute scan. Video tapes taken of both the pre and post mock embryo transfer will be assessed by two researchers who will be unaware of treatment.

20 patients allocated to the nitric oxide group, 20 to the non-steroidal anti-inflammatory group, 20 control and 20 to the COX-2 inhibitor group.

## Intervention Type

Drug

#### Phase

Not Applicable

## Primary outcome measure

- 1. Number of contractions per unit time
- 2. Speed of contractions in cm/min
- 3. Type of contractions
- 4. Speed of Echovist
- 5. Distance traveled by Echovist

## Secondary outcome measures

Not provided at time of registration

# Overall study start date

01/04/2000

# Completion date

10/12/2003

# **Eligibility**

## Key inclusion criteria

Not provided at time of registration

# Participant type(s)

**Patient** 

#### Age group

Adult

#### Sex

Female

# Target number of participants

80

## Key exclusion criteria

Not provided at time of registration

#### Date of first enrolment

01/04/2000

#### Date of final enrolment

10/12/2003

# Locations

#### Countries of recruitment

England

#### **United Kingdom**

Study participating centre The Princess Royal Hospital Hull United Kingdom HU8 9HE

# Sponsor information

## Organisation

Department of Health

# Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

## Sponsor type

Government

#### Website

http://www.dh.gov.uk/Home/fs/en

# Funder(s)

# Funder type

Research organisation

#### **Funder Name**

The North and South Bank Research and Development Consortium (UK)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

# Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration